El tratamiento contra el covid-19 que recomienda la OMS

La Organización Mundial de la Salud formuló una recomendación a favor del uso de nirmatrelvir y ritonavir,

[{"selector":"#anim-1f809abb-adb1-4bee-a287-bf3fa4437b9c","keyframes":{"opacity":[0,1]},"delay":0,"duration":600,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-fa300bcc-87ae-412b-9fe6-2be789fb383e","keyframes":{"transform":["translate3d(-105.39084%, 0px, 0)","translate3d(0px, 0px, 0)"]},"delay":0,"duration":600,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}]

Ha descrito el tratamiento como la mejor opción terapéutica hasta la fecha en pacientes de alto riesgo.

[{"selector":"#anim-a7931e04-795d-466a-bf18-2b1ac8321828","keyframes":{"opacity":[0,1]},"delay":0,"duration":600,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-af4d0a71-cf03-4f76-8244-5a4e4f78f01a","keyframes":{"transform":["translate3d(-105.39084%, 0px, 0)","translate3d(0px, 0px, 0)"]},"delay":0,"duration":600,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}]

Sin embargo, varios elementos han hecho que este medicamento sea un problema para los países de ingresos bajos y medianos.

[{"selector":"#anim-9b8f26b1-7f82-4080-b3ce-f392b14db48e","keyframes":{"opacity":[0,1]},"delay":0,"duration":600,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-1d72088c-5fa2-4dee-8ac7-55310ff80944","keyframes":{"transform":["translate3d(-105.39084%, 0px, 0)","translate3d(0px, 0px, 0)"]},"delay":0,"duration":600,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}]

Uno de los obstáculos es que solo puede administrarse en las etapas iniciales de la enfermedad

[{"selector":"#anim-c5c5399c-8ec3-4072-85a4-6741711ad84a","keyframes":{"opacity":[0,1]},"delay":0,"duration":600,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-0d3c8f76-cd22-4d82-8071-e494f0dd37a0","keyframes":{"transform":["translate3d(-105.39084%, 0px, 0)","translate3d(0px, 0px, 0)"]},"delay":0,"duration":600,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}]

La OMS pide mejorar el acceso a las pruebas y el diagnóstico temprano en los entornos de atención primaria de salud

[{"selector":"#anim-072ec3ea-cb50-4622-a00d-4efb03bdab40","keyframes":{"opacity":[0,1]},"delay":0,"duration":600,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-c3d95e14-a4c4-46f9-833d-670c22bfc1d8","keyframes":{"transform":["translate3d(-105.39084%, 0px, 0)","translate3d(0px, 0px, 0)"]},"delay":0,"duration":600,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}]

Y a Pfizer recomienda mejorar la transparencia de sus precios, acuerdos y que amplíe el alcance geográfico de su licencia

[{"selector":"#anim-a69e33be-5d49-4388-a19b-512dd9d63459","keyframes":{"opacity":[0,1]},"delay":0,"duration":600,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-89677887-dcdb-4af8-8742-1afefacef080","keyframes":{"transform":["translate3d(-105.39084%, 0px, 0)","translate3d(0px, 0px, 0)"]},"delay":0,"duration":600,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}]

De igual forma, la OMS actualizó su recomendación sobre remdesivir, otro antirretrovírico.

[{"selector":"#anim-c74fe70f-9118-4691-b8b3-a68361003976","keyframes":{"opacity":[0,1]},"delay":0,"duration":600,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-e087eaf1-409a-49c1-b45e-b128db05ed18","keyframes":{"transform":["translate3d(-105.39084%, 0px, 0)","translate3d(0px, 0px, 0)"]},"delay":0,"duration":600,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}]